186 related articles for article (PubMed ID: 7229976)
21. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and bioavailability of three dyphylline preparations.
Stablein JJ; Samaan SS; Bukantz SC; Lockey RF
Eur J Clin Pharmacol; 1983; 25(2):281-3. PubMed ID: 6628514
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetics of theophylline, proxyphylline and diprophylline in a combination preparation in healthy probands].
Schmäschke J; Oellerich M; Schumann G; Sybrecht GW
Prax Klin Pneumol; 1985 Jan; 39(1):19-27. PubMed ID: 3975213
[No Abstract] [Full Text] [Related]
24. Hemodialysis of theophylline in uremic patients.
Lee CS; Marbury TC; Perrin JH; Fuller TJ
J Clin Pharmacol; 1979 Apr; 19(4):219-26. PubMed ID: 438357
[TBL] [Abstract][Full Text] [Related]
25. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
26. Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.
Lee CS; Peterson JC; Marbury TC
J Clin Pharmacol; 1983 Jul; 23(7):274-80. PubMed ID: 6886029
[TBL] [Abstract][Full Text] [Related]
27. Hemodialysis clearance of total and unbound lidocaine.
Jacobi J; McGory RW; McCoy H; Matzke GR
Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
[TBL] [Abstract][Full Text] [Related]
28. Probenecid inhibition of the renal excretion of dyphylline in chicken, rat and man.
Acara M; Carr EA; Terry EN
J Pharm Pharmacol; 1987 Jul; 39(7):526-30. PubMed ID: 2886621
[TBL] [Abstract][Full Text] [Related]
29. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
30. Bioavailability of dyphylline and dyphylline-guaifenesin tablets in humans.
Straughn AB; Wood GC; Raghow G; Meyer MC
J Pharm Sci; 1985 Mar; 74(3):335-7. PubMed ID: 4009445
[TBL] [Abstract][Full Text] [Related]
31. Dialysis clearance of buflomedil in hemodialysed patients.
Rey E; Moynot A; d'Athis P; Pello JY; Maurel A; Frydman MO; Buisson C; Olive G
Arzneimittelforschung; 1996 May; 46(5):492-5. PubMed ID: 8737633
[TBL] [Abstract][Full Text] [Related]
32. Effect of hemodialysis on total body clearance of chloramphenicol.
Slaughter RL; Cerra FB; Koup JR
Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
Chodos J; Francke EL; Saltzman M; Neu HC
Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
[TBL] [Abstract][Full Text] [Related]
35. Utilization of intravenous dihydroxypropyl theophylline (dyphylline) in an aminophylline-sensitive patient, and its pharmacokinetic comparison with theophylline.
Lawyer CH; Bardana EJ; Rodgers R; Gerber N
J Allergy Clin Immunol; 1980 May; 65(5):353-7. PubMed ID: 7372953
[TBL] [Abstract][Full Text] [Related]
36. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
Schaedeli F; Uehlinger DE
Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
[TBL] [Abstract][Full Text] [Related]
37. Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis.
Wolter K; Claus M; Wagner K; Fritschka E
Clin Nephrol; 1994 Dec; 42(6):389-97. PubMed ID: 7882603
[TBL] [Abstract][Full Text] [Related]
38. The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial.
Wang W; Tonelli M; Hemmelgarn B; Gao S; Johnson JA; Taub K; Manns B;
Am J Kidney Dis; 2008 May; 51(5):796-803. PubMed ID: 18436090
[TBL] [Abstract][Full Text] [Related]
39. Hemodialysis clearance of chloroquine in uremic patients.
Akintonwa A; Odutola TA; Edeki T; Mabadeje AF
Ther Drug Monit; 1986; 8(3):285-7. PubMed ID: 3750371
[TBL] [Abstract][Full Text] [Related]
40. Increasing dialysate flow rate increases dialyzer urea clearance and dialysis efficiency: an in vivo study.
Azar AT
Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1023-9. PubMed ID: 19861865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
